Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius SE & Co. KGaA    FRE   DE0005785604

FRESENIUS SE & CO. KGAA

(FRE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius : 3Q Net Profit, Sales Grew; Backs Outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/29/2019 | 01:45am EST

By Carlo Martuscelli

Fresenius SE & Co. KGaA (FRE.XE) said Tuesday that net profit and sales both rose in the third quarter, and backed its full-year outlook.

Net income was 444 million euros ($492.4 million), up from EUR419 million in the previous-year period, while sales grew 7.9% to EUR8.42 billion.

The German provider of health products and services backed its earnings guidance for 2019. The company sees sales growth at constant currency rates of between 4% to 7%, while net income on a comparable basis is expected to be flat.

At Fresenius Medical Care, the company's dialysis division, net profit rose 17% to EUR333 million, while sales increased by 8.9% to EUR4.42 billion.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com; @carlomartu

Stocks mentioned in the article
ChangeLast1st jan.
FRESENIUS MEDICAL CARE AG & CO. KGAA 0.59% 65.06 Delayed Quote.14.19%
FRESENIUS SE & CO. KGAA 0.27% 49.555 Delayed Quote.16.61%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FRESENIUS SE & CO. KGAA
08:45aFRESENIUS SE & CO. KGAA : Preliminary announcement of the publication of quarter..
EQ
08:40aFRESENIUS SE & CO. KGAA : Preliminary announcement of the publication of financi..
EQ
11/30FRESENIUS SE & CO. KGAA : Release according to Article 41 of the WpHG [the Germa..
EQ
11/15Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations..
AQ
11/11FRES &C : Fresenius Kabi AG - Omega-3 fatty-acid enriched parenteral nutrition i..
AQ
11/06International companies to host live webcasts at Deutsche Bank's Depositary R..
AQ
11/05FRESENIUS : Vamed wins awards for spa and wellness facilities
PU
11/04FRESENIUS : Helios acquires medical diagnostics provider in Colombia
PU
11/04FRESENIUS : Buys Colombia's CediMed in EUR40 Million Investment
DJ
11/01FRESENIUS : Medical Care North America achieves strongest quality ratings to dat..
PU
More news
Financials (EUR)
Sales 2019 35 347 M
EBIT 2019 4 588 M
Net income 2019 1 824 M
Debt 2019 19 215 M
Yield 2019 1,64%
P/E ratio 2019 14,7x
P/E ratio 2020 13,7x
EV / Sales2019 1,32x
EV / Sales2020 1,22x
Capitalization 27 616 M
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 55,42  €
Last Close Price 49,56  €
Spread / Highest target 50,9%
Spread / Average Target 11,8%
Spread / Lowest Target -34,5%
EPS Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors